# Grace Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Grace Therapeutics, Inc.). ## Overview Grace Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing proprietary drug delivery formulations for rare and orphan diseases. The company is advancing a small pipeline of drug candidates, with GTx-104 as its lead program, and has not yet generated product revenue. ## Products & services • GTx-104 clinical-stage drug candidate for rare/orphan diseases • Proprietary drug delivery formulations for approved compounds • GTx-102 development program • GTx-101 development program • Clinical development, regulatory filing, and commercialization preparation - **Lead drug candidate programs** (0%) — Clinical-stage product candidates being developed for rare and orphan disease indications. - **Drug delivery technology platform** (0%) — Proprietary formulations designed to improve efficacy, onset, tolerability, and compliance of existing compounds. - **Regulatory and development services** (0%) — Internal R&D, clinical development, and FDA submission work supporting pipeline advancement. - **Future commercialization** (0%) — Potential post-approval sales, marketing, and distribution of approved drug products. - GTx-104 lead clinical-stage candidate - Proprietary formulations for rare and orphan diseases - GTx-102 development program - GTx-101 development program - Clinical trial and NDA preparation activities - Drug delivery technology platform ## Customers The company does not yet sell commercial products, so its near-term 'customers' are primarily regulators, clinical investigators, CROs, CMOs, and potential future licensing or commercialization partners. If approved, its end customers would be physicians, pharmacists, hospitals, and patients treating rare and orphan diseases, with reimbursement decisions also influencing adoption. - **Regulators and clinical development partners** (primary) — FDA, CROs, and CMOs that support clinical testing, manufacturing, and approval pathways for the pipeline. - **Future prescribing physicians and hospitals** (primary) — Specialists and care settings that would use approved products for rare and orphan disease treatment. - **Payers and government reimbursement programs** (secondary) — Medicaid, Medicare Part B, 340B entities, and other payors that affect pricing and access after approval. - **Strategic partners and licensors** (secondary) — Potential commercialization partners for larger-market products such as GTx-101. - FDA and other regulators for NDA review and approval - CROs and CMOs that execute trials and manufacture clinical supply - Potential strategic partners for GTx-101 commercialization - Physicians, pharmacists, and patients if products are approved - Payers and government programs that determine reimbursement access ## Geography Grace Therapeutics is headquartered and operationally concentrated in the United States, where all six full-time employees were located as of March 31, 2025. Its current development, regulatory, and potential commercialization activities are U.S.-centric, although its intellectual property portfolio spans multiple jurisdictions worldwide. - All full-time employees are located in the United States - Clinical and regulatory work is centered on the U.S. market - Potential commercialization is expected to start in the United States - IP portfolio covers multiple jurisdictions worldwide - No country revenue disclosure is available because there is no product sales base ## Strategy The company’s strategy is to advance its rare-disease pipeline, complete development for GTx-104, and pursue FDA approval while preserving optionality for GTx-102 and GTx-101. Because it has no product revenue, the near-term strategic priority is financing the business through equity, debt, or non-dilutive collaborations until a commercial asset is approved. - **Advance GTx-104 to regulatory approval** (short-term) — This is the lead asset and the most direct path to first commercial revenue. - **Secure additional financing** (short-term) — The company expects continued operating losses and needs capital before cash runs out. - **Build commercialization readiness** (medium-term) — Approval alone is not enough; the company needs sales, marketing, and distribution capability. - Complete clinical development and NDA submission for GTx-104 - Preserve optionality on GTx-102 and GTx-101 programs - Seek regulatory approval to unlock first product revenue - Raise additional capital to fund operations and trials - Evaluate partnerships for larger-market commercialization ## Risks Grace Therapeutics is exposed to classic clinical-stage biotech risks: trial failure, regulatory delay, financing risk, and uncertainty around eventual market acceptance. It also faces manufacturing, intellectual property, and reimbursement risks that can materially affect whether any approved product can be produced, protected, and sold profitably. - **Clinical development failure or delay** [critical] — The company depends on successful trials and FDA approval to create any product revenue. - **Financing and liquidity shortfall** [critical] — Management expects to need additional capital before current resources are exhausted. - **Manufacturing and supply chain disruption** [high] — Clinical and future commercial supply depend on third-party CMOs meeting cGMP and quality requirements. - **Intellectual property challenges** [high] — Third-party patent claims or weak protection could limit commercialization or increase costs. - **Reimbursement and pricing pressure** [medium] — Medicaid, Medicare Part B, and 340B rules can reduce realized pricing after approval. - No product revenue until approval, so development setbacks can extend losses - Additional capital may be unavailable or highly dilutive - Clinical trials may fail or support an unfavorable FDA review - CMO/CRO execution issues can delay studies or supply - Patent disputes could force redesign, royalties, or litigation - Reimbursement and 340B/Medicaid pricing can pressure future margins ## Accounting The most important accounting judgments are R&D accruals, fair value changes in derivative warrant liabilities, and valuation of acquired intangible assets and goodwill. Because the company is pre-revenue and loss-making, these estimates can materially swing reported earnings and balance-sheet values from period to period. - **Research and development accruals** — Can shift quarterly R&D expense and liabilities - **Derivative warrant liabilities** — Can materially affect net income/loss - **Intangible asset and goodwill impairment** — Could cause large impairment charges - **Stock-based compensation** — Raises operating expenses and affects per-share results - R&D is expensed as incurred, with accruals based on work performed - Derivative warrant liabilities create fair value volatility in earnings - Acquired IPR&D and goodwill are subject to impairment risk - Stock-based compensation affects operating expenses and loss per share - Research tax credits depend on management judgment and realizability --- *Last updated: 2026-04-28T20:11:57.367728+00:00*